QSAR analysis of pyrazolidine-3,5-diones derivatives as Dyrk1A inhibitors

Individuals with Down syndrome (DS) suffer from mental retardation. Overexpression and the resulting increased specific activity of Dyrk1A kinase located on chromosome 21 cause a learning and memory deficit in Dyrk1A transgenic mice. To search for therapeutic agents with Dyrk1A inhibition activity, previously we obtained HCD160 as a new hit compound for Dyrk1A inhibition. In the present study, we synthesized 34 HCD160 derivatives to investigate the quantitative structure–activity relationship (QSAR). This analysis could provide important information for novel drug discovery for treatment of DS related learning and memory deficits.

Graphical abstractThe QSAR analysis of 34 pyrazolidine-3,5-diones derivatives of HCD160 showed that the presence of the 3-nitro-4-hydroxyphenyl moiety enhanced the inhibition activity for Dyrk1A.Figure optionsDownload full-size imageDownload as PowerPoint slide